Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95% confidence interval [CI], 0.78 to 2.64; P=0.01 for noninferiority). Major bleeding occurred in 13 patients in the dabigatran group (0.9%) and 25 patients in the warfarin group (1.8%) (hazard ratio, 0.52; 95% CI, 0.27 to 1.02). Major or clinically relevant bleeding was less frequent with dabigatran (hazard ratio, 0.54; 95% CI, 0.41 to 0.71). Acute coronary syndromes occurred in 13 patients in the dabigatran group (0.9%) and 3 patients in the warfarin group (0.2%) (P=0.02). In the placebo-control study, recurrent venous thromboembolism occurred in 3 of 681 patients in the dabigatran group (0.4%) and 37 of 662 patients in the placebo group (5.6%) (hazard ratio, 0.08; 95% CI, 0.02 to 0.25; P<0.001). Major bleeding occurred in 2 patients in the dabigatran group (0.3%) and 0 patients in the placebo group. Major or clinically relevant bleeding occurred in 36 patients in the dabigatran group (5.3%) and 12 patients in the placebo group (1.8%) (hazard ratio, 2.92; 95% CI, 1.52 to 5.60). Acute coronary syndromes occurred in 1 patient each in the dabigatran and placebo groups. CONCLUSIONS: Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo. (Funded by Boehringer Ingelheim; RE-MEDY and RE-SONATE ClinicalTrials.gov numbers, NCT00329238 and NCT00558259, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients who are treated with dabigatran for secondary prevention, only the standard regimen of 150 mg twice daily has been studied. 310”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Self-citation(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Self-citationKearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationNewly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Research works printed but not linked: 1
- 8. Cochrane Database Syst Rev 2000;3: CD001367.
Cited by
Items 301–400 of 1,000
Phillippe, H. M., Hornsby, L. B., Eudaley, S. T., Armstrong, E. M., & Bellone, J. M. (2014) · Journal of Pharmacy Practice · doi:10.1177/0897190014530390 · Cited by 29
Sindet-Pedersen, C., Pallisgaard, J. L., Olesen, J. B., Gislason, G. H., & Arevalo, L. C. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.022 · Cited by 22
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy
Finks, S. W., Trujillo, T. C., & Dobesh, P. P. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016632785 · Cited by 24
“Although a significant increase in major bleeding was not observed in the DOAC arms in any of these trials, the rates of major/CRNM bleeding were increased with each of these agents (Table 4), with most differences found in hematuria, epistaxis, and/or rectal bleeding.(39,47,48) Furthermore, the incidence of major/CRN…”
Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment
Schindewolf, M., & Weitz, J. I. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-3400302 · Cited by 23
Diagnosis and treatment of acute pulmonary embolism
Widimsky, J., Jr. (2013) · Cor et Vasa · doi:10.1016/j.crvasa.2013.10.001 · Cited by 22
Li, H., Zhong, J.-Q., Zhang, W., Rong, B., Xie, F., Wang, J., Yue, X., Zheng, Z., Zhu, Q., & Zhang, Y. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.104 · Cited by 22
“Non-valvular atrial fibrillation Transesophageal echocardiography Intracardiac thrombus Dabigatran Warfarin VTE recurrence and a lower risk of hemorrhage comparedwithwarfarin [6,7].”
BackgroundIt's time for head-to-head trials with direct oral anticoagulants
Tritschler, T., & Castellucci, L. A. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2019.05.019 · Cited by 24
Yamashita, Y., Yoshikawa, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.06.032 · Cited by 25
Direct-Acting Oral Anticoagulants in Critically Ill Patients
Rali, P. M., Gangemi, A. J., Moores, A., Mohrien, K. M., & Moores, L. K. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.05.025 · Cited by 24
Ceresetto, J. M. (2016) · Clinics · doi:10.6061/clinics/2016(01)07 · Cited by 25
“The results of key studies of each of the DOACs are summarized in Table 2 (64-71).”
BackgroundBromley, A., & Plitt, A. (2018) · Cardiology and Therapy · doi:10.1007/s40119-018-0107-0 · Cited by 21
“The extended treatment with dabigatran was studied in the RE-SONATE and RE-MEDY trials.”
BackgroundMethodInfluentialCohen, A. T., Berger, S. E., Milenković, D., Hill, N. R., & Lister, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.017 · Cited by 22
Ebraheem, M. S., Alzahrani, I., Crowther, M. A., Rochwerg, B. N., & Almakadi, M. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14949 · Cited by 22
Extended Anticoagulation After Pulmonary Embolism: A Multicenter Observational Cohort Analysis
Chopard, R., Albertsen, I. E., Ecarnot, F., Guth, S., Besutti, M., Falvo, N., Piazza, G., & Meneveau, N. F. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024425 · Cited by 22
Kovac, M. K., Ignjatović, V., Orlando, C., Bereczky, Z., & Hunt, B. J. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.08.006 · Cited by 21
Optimal treatment duration of venous thrombosis
Ageno, W., Dentali, F., Donadini, M. P., & Squizzato, A. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12234 · Cited by 21
Grandoni, F., & Alberio, L. (2019) · Cancers · doi:10.3390/cancers11010046 · Cited by 23
“In the subgroup analysis, 655 patients were randomly assigned to receive rivaroxaban versus VKAs (EINSTEIN-DVT and EINSTEIN-PE trials) [29,30,45], 771 patients assigned to receive edoxaban versus VKAs (Hokusai-VTE) [32,46], 335 patients assigned to receive dabigatran versus VKAs [33,47,48], and 159 patients assigned t…”
MethodPompilio, G., Integlia, D., Raffetto, J. D., & Palareti, G. (2020) · TH Open · doi:10.1055/s-0040-1709731 · Cited by 21
Oral anticoagulants in the management of venous thromboembolism
Makaryus, J. N., Halperin, J. L., & Lau, J. F. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.73 · Cited by 28
Sciascia, S., Radin, M., Schreiber, K. I., Fenoglio, R., Baldovino, S., & Roccatello, D. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1753-2 · Cited by 22
Eighty years of oral anticoagulation: Learning from history
Montinari, M. R., Minelli, S., & Caterina, R. D. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106918 · Cited by 21
Bauersachs, R. M. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.05.017 · Cited by 20
“555, respectively) [54].”
BackgroundInfluentialNew Anticoagulants and Antiplatelet Agents: A Primer for the Clinical Gastroenterologist
Parekh, P. J., Merrell, J., Clary, M., Brush, J. E., & Johnson, D. A. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.228 · Cited by 20
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism
Fontana, P., Goldhaber, S. Z., & Bounameaux, H. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu027 · Cited by 22
“placebo in separate extension studies published together in the same manuscript.(16) The patients included must have received an initial phase of at least 3 (RE-MEDY) or 6 (RE-SONATE) months of anticoagulation.”
BackgroundResultSelf-citationDirect oral anticoagulants: unique properties and practical approaches to management
Barnes, G. D., & Kurtz, B. (2016) · Heart · doi:10.1136/heartjnl-2015-309075 · Cited by 20
Li, M., Li, J., Wang, X., Xu, H., Wang, Q., Xie, S., Yan, P., Tian, J., Li, J., Xie, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010957.pub3 · Cited by 26
Jiang, Q., Bai, J., Jin, J., Shi, J., & Qu, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00876 · Cited by 20
“Clinical trials have shown that the efficacies of new oral anticoagulants (NOACs) and aspirin are non-inferior to warfarin (Becattini et al., 2012; Agnelli et al., 2013; Schulman et al., 2013).”
BackgroundChoice and Duration of Anticoagulation for Venous Thromboembolism
Barnes, G. D., Malik, A., & Ha, N. B. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13010301 · Cited by 26
Talerico, R., Pola, R., Klok, F. A., & Huisman, M. V. (2024) · TH Open · doi:10.1055/s-0043-1776989 · Cited by 20
Diretrizes sobre trombose venosa profunda da Sociedade Brasileira de Angiologia e Cirurgia Vascular
Sobreira, M. L., Marques, M. A., Paschôa, A. F., Ribeiro, A. J. A., Casella, I. B., Burihan, M. C., Matielo, M. F., Soares, R. D. A., de Araújo, W. J. B., Joviliano, E. É., et al. (2024) · Jornal Vascular Brasileiro · doi:10.1590/1677-5449.202301071 · Cited by 27
Prandoni, P. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.05.013 · Cited by 21
“02) [29].”
BackgroundResultInfluentialClinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism
Bacchus, F., & Schulman, S. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303396 · Cited by 23
“For extended treatment of VTE, dabigatran was studied in 2 RCTs at a dose of 150 mg twice daily, after ≥3 months of initial anticoagulant treatment.(24) In RE-SONATE, patients”
BackgroundSelf-citationRiess, H. B., Habbel, P., Jühling, A., Sinn, M., & Pelzer, U. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i3.258 · Cited by 19
Yasaka, M., Ikushima, I., Harada, A., Imazu, S., Taniguchi, A., Norris, S. H., Ganßer, D., Stangier, J., Schmohl, M., & Reilly, P. A. (2017) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12029 · Cited by 19
Röshammar, D., Huang, F., Albisetti, M., Bomgaars, L. R., Chalmers, E. A., Luciani, M., Halton, J., Mitchell, L. G., Bergstrand, M., Ibrahim, M. M. A., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15277 · Cited by 21
Chen, J., Lv, M., Wu, S., Jiang, S., Xu, W., Qian, J., Chen, M., Fang, Z., Zeng, Z., & Zhang, J. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2021.10.054 · Cited by 21
The Association of Direct Thrombin Inhibitor Anticoagulants With Cardiac Thromboses
Davidson, B. L. (2014) · CHEST Journal · doi:10.1378/chest.14-2028 · Cited by 20
Direct oral anticoagulants: integration into clinical practice
Cowell, R. P. W. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-132474 · Cited by 23
Statin Therapy to Revert Hypercoagulability and Prevent Venous Thromboembolism: A Narrative Review
Orsi, F. A., Cannegieter, S. C., & Lijfering, W. M. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1687911 · Cited by 21
Anticoagulation management strategies in heart transplantation
Rizk, J. G., & Mehra, M. R. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.02.002 · Cited by 19
Rollins, B. M., Silva, M. A., Donovan, J. L., & Kanaan, A. O. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.033 · Cited by 18
Coleman, C. I., Limone, B. L., Bookhart, B. K., Mody, S. H., & Nutescu, E. A. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.02.006 · Cited by 18
“While each of these agents have been compared to placebo for extended VTE treatment [1,6,7,13,4,18,40–43], only dabigatran [42] has been compared to warfarin as part of a head-to-head randomized trial.”
BackgroundMethodInfluentialNovel Oral Anticoagulants for Atrial Fibrillation
Hankey, G. J., & Eikelboom, J. W. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0344-6 · Cited by 19
Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review
van der Wall, S. J., van der Pol, L. M., Ende-Verhaar, Y. M., Cannegieter, S. C., Schulman, S., Prandoni, P., Rodger, M. A., Huisman, M. V., & Klok, F. A. (2018) · European Respiratory Review · doi:10.1183/16000617.0094-2018 · Cited by 20
“eleven (92%) included autopsy and/or clinical suspicion [18, 19, 22, 24, 25, 27, 30, 31, 36-38] and five (42%) involved ‘sudden unexplained death’ [25, 27, 34, 36, 37].”
BackgroundSelf-citationWeitz, J. I., & Chan, N. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1679906 · Cited by 18
Rivera‐Caravaca, J. M., Harrison, S. L., Buckley, B. J. R., Fazio‐Eynullayeva, E., Underhill, P., Marín, F. R., & Lip, G. Y. H. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01368-6 · Cited by 18
Thrombophilia Testing, Recurrent Thrombosis, and Women’s Health
Piazza, G. (2014) · Circulation · doi:10.1161/circulationaha.113.007664 · Cited by 19
Alshammari, T. M., Ata, S. I., Mahmoud, M. A., Alhawassi, T. M., & Aljadhey, H. S. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s161148 · Cited by 21
Woller, S. C., Stevens, S. M., Johnson, S. A., Bledsoe, J. R., Galovic, B., Lloyd, J. F., Wilson, E. L., Armbruster, B. P., & Evans, R. S. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12208 · Cited by 21
Uresandi, F., Monréal, M., García-Bragado, F., Domenech, P., Lecumberri, R., Escribano, P., Zamorano, J. L., Jiménez, S., Ruiz‐Artacho, P., Lozano, F., et al. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2013.10.008 · Cited by 40
Bova, C., Bianco, A., Mascaro, V., & Nobile, C. G. A. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.01.005 · Cited by 18
Maas, H. J., Gropper, S., Huang, F., Stangier, J., Tartakovsky, I. S., Brueckmann, M., Halton, J., & Mitchell, L. G. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1668132 · Cited by 19
Extended Treatment of Venous Thromboembolism
Connors, J. M. (2013) · New England Journal of Medicine · doi:10.1056/nejme1215678 · Cited by 19
Su, X., Yan, B., Wang, L., Cheng, H., & Chen, Y. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-048619 · Cited by 17
Expanding use of new oral anticoagulants
Weitz, J. I. (2014) · F1000Prime Reports · doi:10.12703/p6-93 · Cited by 18
“For extended VTE treatment, rivaroxaban, apixaban, and dabigatran were compared with placebo in the EINSTEINEXTENSION, AMPLIFY-Extension, and RE-SONATE trials, respectively [21,27,28].”
BackgroundMethodWho should get long-term anticoagulant therapy for venous thromboembolism and with what?
Rodger, M. A., & Gal, G. L. (2018) · Hematology · doi:10.1182/asheducation-2018.1.426 · Cited by 17
Papakonstantinou, P. Ε., Tsioufis, C. P., Konstantinidis, D., Iliakis, P., Leontsinis, I., & Tousoulis, D. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200420150517 · Cited by 17
Bleeding complications of targeted oral anticoagulants: what is the risk?
Levine, M., & Goldstein, J. N. (2014) · Hematology · doi:10.1182/asheducation-2014.1.504 · Cited by 20
Konstantinides, S., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D. A., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M. J. C., Kucher, N., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.12.002 · Cited by 25
Direct oral anticoagulants: a guide for daily practice
Fontana, P., Robert‐Ebadi, H., Bounameaux, H., Boehlen, F., & Righini, M. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14286 · Cited by 22
Terleira‐Fernández, A. I., Lecumberri, R., Suárez‐Gea, M. L., Calvo, G., Vargas, E., & Gómez‐Outes, A. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1642644 · Cited by 17
Sebastian, T., Engelberger, R. P., Spirk, D., Hakki, L. O., Baumann, F. A., Spescha, R. S., & Kucher, N. (2019) · VASA · doi:10.1024/0301-1526/a000774 · Cited by 17
Rivaroxaban for the Treatment of Pulmonary Embolism
Vanassche, T., & Verhamme, P. B. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0041-4 · Cited by 18
“Rivaroxaban was the first drug to receive regulatory approval for the treatment of VTE, but it is expected that dabigatran, apixaban, and edoxaban will also become available for this indication, as these drugs are in their final phases of their clinical development programmes or regulatory approval [12–15].”
BackgroundTrends in Pulmonary Embolism Outcomes
Konstantinides, S. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.062 · Cited by 17
Bleeding Risk in Hemodialysis Patients
van der Sluijs, A. V. E., Pai, P. M., Zhu, W., & Ocak, G. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151478 · Cited by 18
Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid
Bejjani, A., & Bikdeli, B. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2451-4014 · Cited by 18
Alberio, L. (2014) · Seminars in Hematology · doi:10.1053/j.seminhematol.2014.03.002 · Cited by 16
Lanitis, T., Leipold, R. J., Hamilton, M., Rublee, D. A., Quon, P., Browne, C., & Cohen, A. T. (2017) · BMC Health Services Research · doi:10.1186/s12913-017-1995-8 · Cited by 16
“For example, out of the four VKA trials included in the analysed network, REMEDY [27] specifically included patients at high risk of VTE previously treated for 3–12 months, and LAFIT [4] and the WODIT [28, 29] trials included patients previously treated for 3 months, excluding those who had an indication for continuin…”
MethodReversing the anticoagulation effects of dabigatran
Dager, W. E., & Banares, L. (2017) · Hospital Practice · doi:10.1080/21548331.2017.1298389 · Cited by 18
Glund, S., Gan, G., Moschetti, V., Reilly, P. A., Honickel, M., Grottke, O., & van Ryn, J. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618755947 · Cited by 16
Recent advances in understanding, diagnosing and treating venous thrombosis
Chan, N., & Weitz, J. I. (2020) · F1000Research · doi:10.12688/f1000research.27115.1 · Cited by 18
Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis
Wallace, E., & Smyth, S. S. (2013) · Pharmaceuticals · doi:10.3390/ph6080915 · Cited by 19
“On the other hand, dabigatran has been associated with higher rates of MI in several analyses of data from non-ACS trials [38,41].”
Ageno, W., Casella, I. B., Han, C. K., Raskob, G. E., Schellong, S., Schulman, S., Singer, D. E., Kimura, K. A., Tang, W., Desch, M., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-07-0566 · Cited by 16
Self-citationWakakura, S., Hara, F., Fujino, T., Hamai, A., Ohara, H., Kabuki, T., Harada, M., & Ikeda, T. (2017) · International Heart Journal · doi:10.1536/ihj.16-482 · Cited by 16
Yan, Y., Zhang, C., Shen, L., Su, Y.-J., Liu, X., Wang, L., & Gu, Z. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00575 · Cited by 16
the COMMAND VTE Registry Investigators, Yamashita, Y., Morimoto, T., Amano, H., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., et al. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1791-2 · Cited by 16
Management of pulmonary embolism: recent evidence and the new European guidelines
Konstantinides, S., & Torbicki, A. (2014) · European Respiratory Journal · doi:10.1183/09031936.00180414 · Cited by 19
Anticoagulation therapy in 2015: where we are and where we are going
Weitz, J. I. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1194-6 · Cited by 15
Evidence Supporting Idarucizumab for the Reversal of Dabigatran
Pollack, C. V. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.008 · Cited by 15
“In clinical trials, dabigatran has been associated with similar or reduced rates of the key safety end points of major and intracranial bleeding, depending on the dose and the indication, as well as similar rates of fatal bleeding comparedwith vitamin K antagonists (VKAs), such aswarfarin [2-4].”
BackgroundEvidence supporting idarucizumab for the reversal of dabigatran
Pollack, C. V. (2016) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2016.09.051 · Cited by 16
Lutsey, P. L., Norby, F. L., Zakai, N. A., MacLehose, R. F., Chen, L. Y., Shah, S., Datta, Y. H., & Alonso, Á. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1541445 · Cited by 16
Lei, J., Xu, X., Ji, Y., Yang, Y., Yi, Q., Chen, H., Hu, X., Liu, Z., Mao, Y., Zhang, J., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.05.087 · Cited by 15
Mavromanoli, A. C., Barco, S., & Konstantinides, S. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12509 · Cited by 15
Bikdeli, B., Hogan, H., Morrison, R. B., Fanikos, J. R., Campia, U., Barns, B. M., Pfeferman, M. B., Snyder, J. E., Khairani, C. D., Goldhaber, S. Z., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1646-2244 · Cited by 16
Self-citationManagement of dabigatran-induced bleeding: expert statement
Fries, D. R., Giurea, A., Gütl, M., Halbmayer, W., Kozek‐Langenecker, S. A., Pachucki, A., Roithinger, F. X., Steinlechner, B., Thaler, H. W., & Weltermann, A. (2013) · Wiener klinische Wochenschrift · doi:10.1007/s00508-013-0430-3 · Cited by 15
“With pending indications for the use of dabigatran in patients with deep vein thrombosis or pulmonary embolism [18, 19], bleeding complications may and will occur in this cohort as well.”
BackgroundBircan, A., & Alanoğlu, E. G. (2015) · Eurasian Journal of Medicine · doi:10.5152/eurasianjmed.2015.95 · Cited by 15
“Dabigatran, an oral thrombin inhibitor, is a new agent for the prevention and treatment of acute VTE and may be a viable treatment option of HIT [1, 9, 11].”
BackgroundAhmed, Z., Hassan, S., & Salzman, G. A. (2016) · Current Drug Therapy · doi:10.2174/1574885511666160421145036 · Cited by 15
“85 allowing almost three times the risk of VTE to still be considered non inferior [18].”
InfluentialStevanović, J., de Jong, L. A., Kappelhoff, B. S., Dvortsin, E., Voorhaar, M., & Postma, M. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163550 · Cited by 17
ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism
D’Agostino, C., Zonzin, P., Enea, I., Gulizia, M. M., Ageno, W., Agostoni, P., Azzarito, M., Becattini, C., Bongarzoni, A., Bux, F., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux030 · Cited by 16
Albisetti, M., Biss, B., Bomgaars, L. R., Brandão, L. R., Brueckmann, M., Chalmers, E. A., Gropper, S., Harper, R., Huang, F., Luciani, M., et al. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12086 · Cited by 16
Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization
Khachatryan, T., Hauschild, C., Hoff, J., Contractor, T. A., Khachatryan, A., Tran, H. N., Matsuo, B., Jacobson, A. K., & Hilliard, A. A. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00344-6 · Cited by 15
Anticoagulation for the initial treatment of venous thromboembolism in people with cancer
Kahale, L. A., Matar, C. F., Hakoum, M. B., Tsolakian, I. G., Yosuico, V. E. D., Terrenato, I., Sperati, F., Barba, M., Schünemann, H. J., & Akl, E. A. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006649.pub8 · Cited by 16
Majeed, A., Hwang, H.-G., Eikelboom, J. W., Connolly, S. J., Wallentin, L. C., Feuring, M., Brueckmann, M., Noack, H., Yusuf, S., & Schulman, S. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.02.005 · Cited by 16
Self-citationDoundoulakis, I., Antza, C., Karvounis, H. I., & Giannakoulas, G. A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200506114450 · Cited by 14
Ткачева, О. Н., Vorobyeva, N. M., Kotovskaya, Y. V., Рунихина, Н. К., Strazhesko, I. D., Вадимовна, В. С., Drapkina, O. M., Komarov, A. L., Orlova, Y. A., Панченко, Е. П., et al. (2021) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2021-2847 · Cited by 15
Schenker, C., Stalder, O., Méan, M., Tritschler, T., Righini, M., Rodondi, N., & Aujesky, D. (2023) · Thrombosis and Haemostasis · doi:10.1055/s-0042-1760365 · Cited by 14
Current State of Anticoagulants to Treat Deep Venous Thrombosis
Vo, T. L., Vazquez, S. R., & Rondina, M. T. (2014) · Current Cardiology Reports · doi:10.1007/s11886-013-0463-2 · Cited by 14
Approach to the new oral anticoagulants in family practice: Part 1: comparing the options
Douketis, J. D., Bell, A., Eikelboom, J. W., & Liew, A. (2014) · Europe PMC (PubMed Central) · doi:10.25405/ncl.34238934 · Cited by 18
Direct oral anticoagulants: efficacy and safety in patient subgroups
Mavrakanas, T. A., Samer, C. F., Fontana, P., & Perrier, A. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14081 · Cited by 14
Yami, M. S. A., Badreldin, H. A., Mohammed, A. H., Elmubark, A., Alzahrani, M., & Alshehri, A. M. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1696-0 · Cited by 15
“Three studies evaluated dabigatran [7, 11, 15].”
Metadata
- Authors
- Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Thrombosis Research Institute (GB)
- Krankenhaus Dresden-Friedrichstadt (DE)
- Sahlgrenska University Hospital (SE)
- Boehringer Ingelheim (Netherlands) (NL)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (United States) (US)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 709-718
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112378432
- Cited by
- 983
- References
- 25
- Citations by year
- 2026: 22 · 2025: 26 · 2024: 42 · 2023: 32 · 2022: 38 · 2021: 65 · 2020: 62 · 2019: 67 · 2018: 90 · 2017: 71 · 2016: 103 · 2015: 124 · 2014: 141 · 2013: 97
- FWCI
- 135.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- dabigatran, warfarin, venous thromboembolism, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, acute coronary syndrome, direct oral anticoagulants, non-inferiority, thromboprophylaxis, thrombolysis, anticoagulant reversal
- MeSH terms
- Dabigatran, Adolescent, Adult, Aged, Aged, 80 and over, Benzimidazoles, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Recurrence, Risk, Warfarin, beta-Alanine, International Normalized Ratio, Venous Thromboembolism, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.